Journal of Pharmacy and Pharmacology · 1985 · 320 citations · 15 references
PharmacyPharmacokineticsPharmacologyBioavailabilityDrug DeliveryOral Drug DeliveryBlood-brain Barrier DeliveryBlood-brain Barrier PenetrationBlood-brain Barrier PharmacologyDrug AbsorptionDrug DispositionHepatic Drug AbsorptionBlood - Brain Barrier UptakeBlood-brain Barrier Drug TransportBlood-brain Barrier PermeabilityGastrointestinal Absorption BarriersNiosomal NanocarriersNiosome Drug DeliveryPharmacokinetics At The Blood-brain BarrierSurfactant-mediated Permeation
Niosomes composed of non‑ionic surfactant, cholesterol, and dicetyl phosphate encapsulating methotrexate were administered intravenously to mice. Intravenous niosomes prolonged circulating methotrexate, with extensive hepatic uptake and increased brain penetration; oral administration enhanced gastrointestinal absorption at certain doses, and the vesicles altered metabolism by reducing formation of 7‑hydroxy methotrexate.
Non-ionic surfactant vesicles (niosomes) prepared from a non-ionic surfactant, cholesterol and dicetyl phosphate and containing methotrexate (MTX) have been administered to mice. Given intravenously the niosomes prolong the levels of MTX in the blood, large amounts of the drug being taken up by the liver. There was also an increased uptake of MTX into the brain, perhaps due to an effect of the niosome components on the permeability of the blood brain barrier. Absorption of the drug from the gastrointestinal tract following oral ingestion, appeared to be increased at some doses; most of the entrapped MTX was taken up by the liver, but uptake of MTX into the brain was also increased. The metabolic profile of the drug is altered by the niosomes which appear to prevent the rapid formation of 7-hydroxy methotrexate.
15
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregory Gregoriadis, C. Swain, E. J. Wills et al. · The Lancet · 1974 · 396 citations
Pharmacy, Oncology, Pharmacology +10